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The vast majority of prostate cancer deaths are caused by metastasis, yet the mechanisms that 
allow primary tumor cells to become invasive are largely unknown. A new study led by Dr. Jared 
Lucas and Cynthia Heinlein in the laboratory of Dr. Pete Nelson (Human Biology and Clinical 
Research Divisions), along with their collaborators, tackled this question by modeling in mice the role 
of a protease (TMPRSS2) in prostate cancer metastasis. TMPRSS2 is a Type II transmembrane 
serine protease (TTSP) that was previously known to be expressed in normal prostate epithelium 
and to be upregulated in aggressive prostate cancers (Lucas et al., 2008), but its role in normal and 
neoplastic prostate development had not previously been determined. "A critical aspect of this study 
involved the multi-disciplinary collaboration with Fred Hutch and UW faculty that brought in expertise 
ranging from pathology to high-throughput small molecule screens", explained Dr. Nelson. 
The authors first directly compared the transcript levels of TMPRSS2, relative to two other TTSPs, 
hepsin and matriptase, both of which had been implicated in prostate cancer, in microdissected 
epithelium from localized or metastatic prostate cancers. Notably, they found that TMPRSS2 was the 
most highly expressed protease. To confirm that TMPRSS2 was elevated in metastatic tissue 
samples, the authors examined metastatic cancer foci from 44 men, and discovered that the majority 
of foci (132 of 166) exhibited high levels of TMPRSS2. Next, the researchers employed 
pharmacological inhibition of androgen signaling in men with localized prostate cancer, as well as a 
castration-resistant mouse xenograft model, to show that TMPRSS2 expression was regulated by 
androgen ligands. Importantly, deletion of TMPRSS2 in a mouse model of prostate cancer (TRAMP 
model) attenuated metastasis to distant solid organs. Further, TMPRSS2-positive, but not 
TMPRSS2-depleted, primary tumor cells injected into mouse tibias promoted tumor growth and bone 
destruction. Together, these results showed that TMPRSS2 indeed promotes prostate cancer 
metastasis and permits survival and growth of prostate cancer cells at distant sites. 
To uncover potential substrates of TMPRSS2 that could account for its metastatic activity, the 
authors screened a large library of synthetic peptides and found a sequence identical to the 
activation sequence of the precursor form of hepatocyte growth factor (pro-HGF). HGF is a ligand for  
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c-Met, an oncogenic receptor tyrosine kinase known to be relevant to prostate cancer invasion. 
Consistent with pro-HGF being a TMPRSS2 substrate, active, but not protease-inactive form of 
TMPRSS2, was able to cleave pro-HGF in vitro, which resulted in c-Met activation. Since HGF- c-
Met signaling has been linked to epithelial to mesenchymal transition (EMT), the authors wondered 
whether such link could be extended to TMPRSS2. Indeed, transcriptional profiling of TRAMP tumor 
cells with or without TMPRSS2 revealed that EMT-asssociated genes were downregulated in the 
absence of TMPRSS2. Finally, to assess if TMPRSS2 would constitute a therapeutic target, the 
researchers screened several different chemical libraries for TMPRSS2 inhibitors and identified a 
bioavailable, FDA-approved compound called bromhexine. In vivo studies showed that 
intraperitoneal injection of bromhexine in TRAMP mice reduced the frequency of metastasis. Overall, 
these studies show that androgen-induced expression of TMPRSS2 potently activates HGF- c-Met 
signaling, which endows prostate tumor cells with invasive and mesenchymal properties. According 
do Dr. Nelson, "The identification of a bioavailable inhibitor of TMPRSS2 provides an opportunity to 
determine if suppressing TMPRSS2 activity can reduce the spread of prostate cancer and 
consequently impair metastatic growth". 
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Image by Alexandre Neves 
In normal prostate epithelium, TMPRSS2 cannot 
access stromal pro-hepatocyte growth factor (pro-
HGF). In neoplasia however, high levels of 
TMPRSS2 cleaves pro-HGF, which in turn activates 
c-Met in cancer cells (CC) to promote metastasis 
and epithelial to mesenchymal transition (EMT). SC: 
secretory epithelial cell; BC: basal epithelial cell; 
BM: basement membrane. 
 
